Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
Research Areas
At a Glance
- Status: Completed Consortium
- Year Launched: 2002
- Initiating Organization: University of Washington
- Initiator Type: Academia
- Disease focus:
Pain - Location: North America
Abstract
Mission
The mission of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) is to develop consensus reviews and recommendations for improving the design, execution, and interpretation of clinical trials of treatments for pain.
Consortium History
The first IMMPACT meeting was held in November 2002, and there have been a total of 17 consensus meetings on clinical trials of treatments for acute and chronic pain in adults and children.
Structure & Governance
Effective July 1, 2011, IMMPACT consensus meetings, publications, and other activities will be conducted under the auspices of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration.
IMMPACT recommendations and systematic reviews have been widely cited and have guided the design of clinical trials, other types of clinical research, and a national survey. Additional consensus meetings are planned, and research initiatives involving the assessment of pain and the design and interpretation of clinical trials are ongoing. IMMPACT has received favorable responses from all of its stakeholders, who believe that this multidisciplinary initiative has made significant contributions to improved understanding of pain and its treatment.
Links/Social Media Feed
Homepage |
Sponsors & Partners
Annovation |
Astellas |
Centrexion Corporation |
Collegium Pharmaceutical |
Depomed |
Horizon Pharma |
Jazz Pharmaceuticals |
Johnson & Johnson |
Lilly |
Olatec Industries LLC |
Pfizer |
Purdue |
Spinifex |
Teva |